** Shares of Shanghai Henlius Biotech 2696.HK drop 11.1% to HK$15.20, their lowest since April 24, 2024
** Stock set for the biggest one-day pct drop since May 2023 and on course for a tenth straight session of decline
** Hong Kong shareholders of Shanghai Henlius Biotech on Wednesday rejected Chinese conglomerate Fosun International's 0656.HK buyout offer, which would have valued the drugmaker at HK$13.37 bln ($1.72 bln)
** Fosun unit Shanghai Fosun Pharmaceutical 2196.HK 600196.SS, which already holds a 59.6% stake in Henlius, had offered HK$24.60 per share in June for the remaining stake
** A requisite majority of H-class shareholders did not approve the buyout, the proposed privatisation will not proceed and the listing of the Henlius's H Shares will be maintained, the companies said
** Hong Kong shares of Fosun Pharmaceutical rise 2.8% and Fosun International climbs 2.4%
** Hong Kong's healthcare index .HSCIH gains 1.5% and Hang Seng Index .HSI adds 1.3%
** Shanghai Henlius stock soared 70.5% last year
($1 = 7.7880 Hong Kong dollars)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.